The medical letter on drugs and therapeutics march 16 2015

The Medical Letter ® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 ISSUE ISSUE No 1433 1464 Volume 56 March 16, 2015 IN THIS ISSUE Drugs for ADHD p 37 VEGF Inhibitors for AMD and Diabetic Macular Edema p 41 In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder p 42 Important Copyright Message FORWARDING OR COPYING IS A VIOLATION OF U.S AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter, Inc publications are protected by U.S and international copyright laws Forwarding, copying or any distribution of this material is prohibited Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited By accessing and reading the attached content I agree to comply with U.S and international copyright laws and these terms and conditions of The Medical Letter, Inc For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769 Published by The Medical Letter, Inc • A Nonprofit Organization The Medical Letter publications are protected by US and international copyright laws Forwarding, copying or any other distribution of this material is strictly prohibited For further information call: 800-211-2769 The Medical Letter ® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 ISSUE ISSUE No 1433 1464 Volume 56 ▶ March 16, 2015 Take CME exams ALSO IN THIS ISSUE VEGF Inhibitors for AMD and Diabetic Macular Edema .p 41 In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder .p 42 Drugs for ADHD Related article(s) since publication Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood.1,2 A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents.3 Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.4,5 The drugs approved by the FDA for treatment of ADHD are listed in Table on pages 38-39 None of these agents (except for short-acting dextroamphetamine) are approved for use in children